Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2017 May 9

PMID 28480300

Citations 20

Authors

Hema Dave

Min Luo

J W Blaney

Shabnum Patel

Cecilia Barese

Conrad Russell Cruz

Elizabeth J Shpall

Catherine M Bollard

Patrick J Hanley

Affiliations

Soon will be listed here.

Abstract

Umbilical cord blood (CB) has emerged as an effective alternative donor source for hematopoietic stem cell transplantation. Despite this success, the prolonged duration of immune suppression following CB transplantation and the naiveté of CB T cells leave patients susceptible to viral infections. Adoptive transfer of ex vivo-expanded virus-specific T cells from CB is both feasible and safe. However, the manufacturing process of these cells is complicated, lengthy, and labor-intensive. We have now developed a simplified method to manufacture a single culture of polyclonal multivirus-specific cytotoxic T cells in less than 30 days. It eliminates the need for a live virus or transduction with a viral vector, thus making this approach widely available and GMP-applicable to target multiple viruses. The use of overlapping PepMixes as a source of antigen stimulation enable expansion of the repertoire of the T cell product to any virus of interest and make it available as a third party "off the shelf" treatment for viral infections following transplantation.

Citing Articles

Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.

Koukoulias K, Papayanni P, Leen A, Vasileiou S Transfus Med Hemother. 2025; 52(1):5-26.

PMID: 39944414 PMC: 11813280. DOI: 10.1159/000540961.

Umbilical cord blood derived cellular therapy: advances in clinical development.

Wang J, Metheny L Front Oncol. 2023; 13:1167266.

PMID: 37274288 PMC: 10232824. DOI: 10.3389/fonc.2023.1167266.

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients.

Koldehoff M, Eiz-Vesper B, Maecker-Kolhoff B, Steckel N, Dittmer U, Horn P Vaccines (Basel). 2023; 11(4).

PMID: 37112757 PMC: 10141379. DOI: 10.3390/vaccines11040845.

Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.

Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E Hemasphere. 2023; 7(1):e809.

PMID: 36698615 PMC: 9831191. DOI: 10.1097/HS9.0000000000000809.

Therapeutic Perspectives for the Clinical Application of Umbilical Cord Hematopoietic and Mesenchymal Stem Cells: Overcoming Complications Arising After Allogeneic Hematopoietic Stem Cell Transplantation.

Gudauskaite G, Kairiene I, Ivaskiene T, Rascon J, Mobasheri A Adv Exp Med Biol. 2022; 1409:111-126.

PMID: 35995905 DOI: 10.1007/5584_2022_726.

References

Ballen K, Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M . Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(9):1636-1645. PMC: 5008458. DOI: 10.1016/j.bbmt.2016.06.012. View

Eapen M, Rubinstein P, Zhang M, Stevens C, Kurtzberg J, Scaradavou A . Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007; 369(9577):1947-54. DOI: 10.1016/S0140-6736(07)60915-5. View

Milano F, Gooley T, Wood B, Woolfrey A, Flowers M, Doney K . Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med. 2016; 375(10):944-53. PMC: 5513721. DOI: 10.1056/NEJMoa1602074. View

Ruggeri A, Peffault de Latour R, Carmagnat M, Clave E, Douay C, Larghero J . Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis. 2011; 13(5):456-65. DOI: 10.1111/j.1399-3062.2011.00632.x. View

Savoldo B, Cubbage M, Durett A, Goss J, Huls M, Liu Z . Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168(2):909-18. DOI: 10.4049/jimmunol.168.2.909. View

Merindol N, Grenier A, Caty M, Charrier E, Duval A, Duval M . Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells. J Immunol. 2010; 185(2):856-66. DOI: 10.4049/jimmunol.0902613. View

Hanley P, Cruz C, Savoldo B, Leen A, Stanojevic M, Khalil M . Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009; 114(9):1958-67. PMC: 2738578. DOI: 10.1182/blood-2009-03-213256. View

Serrano L, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D . Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood. 2005; 107(7):2643-52. PMC: 1895371. DOI: 10.1182/blood-2005-09-3904. View

Kurtzberg J, Laughlin M, Graham M, Smith C, Olson J, Halperin E . Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996; 335(3):157-66. DOI: 10.1056/NEJM199607183350303. View

10.

Megged O, Stein J, Ben-Meir D, Shulman L, Yaniv I, Shalit I . BK-virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2011; 33(3):190-3. DOI: 10.1097/MPH.0b013e3181fce388. View

11.

Doubrovina E, Oflaz-Sozmen B, Prockop S, Kernan N, Abramson S, Teruya-Feldstein J . Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2011; 119(11):2644-56. PMC: 3311278. DOI: 10.1182/blood-2011-08-371971. View

12.

Hanley P, Cruz C, Shpall E, Bollard C . Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy. 2010; 12(6):713-20. PMC: 3178185. DOI: 10.3109/14653249.2010.517518. View

13.

Geyer M, Jacobson J, Freedman J, George D, Moore V, van de Ven C . A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol. 2011; 155(2):218-34. PMC: 3188698. DOI: 10.1111/j.1365-2141.2011.08822.x. View

14.

Escalon M, Komanduri K . Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Curr Opin Oncol. 2010; 22(2):122-9. DOI: 10.1097/cco.0b013e328335a56e. View

15.

Hanley P, Shaffer D, Cruz C, Ku S, Tzou B, Liu H . Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011; 13(8):976-86. PMC: 3692015. DOI: 10.3109/14653249.2011.575356. View

16.

Szabolcs P, Niedzwiecki D . Immune reconstitution after unrelated cord blood transplantation. Cytotherapy. 2007; 9(2):111-22. PMC: 2203410. DOI: 10.1080/14653240701231014. View

17.

Barker J, Doubrovina E, Sauter C, Jaroscak J, Perales M, Doubrovin M . Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010; 116(23):5045-9. PMC: 3012598. DOI: 10.1182/blood-2010-04-281873. View

18.

Papadopoulou A, Gerdemann U, Katari U, Tzannou I, Liu H, Martinez C . Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014; 6(242):242ra83. PMC: 4181611. DOI: 10.1126/scitranslmed.3008825. View

19.

Gluckman E, Rocha V, Locatelli F, Arcese W, Pasquini R, Ortega J . Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997; 337(6):373-81. DOI: 10.1056/NEJM199708073370602. View

20.

Haque T, McAulay K, Kelly D, Crawford D . Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation. 2010; 90(1):93-4. DOI: 10.1097/TP.0b013e3181d7c424. View